Revolution Medicines, Inc. has presented updated Phase 1 clinical data for zoldonrasib, a selective oral inhibitor targeting the KRAS G12D mutation, at the AACR Annual Meeting. This multicenter trial (RMC-9805-001) specifically focuses on patients with previously treated non-small cell lung cancer (NSCLC) harboring this mutation, which has historically posed a significant challenge in terms of treatment options. The data highlight zoldonrasib’s potential as a promising therapeutic avenue for a patient population with considerable unmet medical needs.

The findings indicate that zoldonrasib has a 52% confirmed objective response rate and a 93% disease control rate among evaluable patients who had undergone prior treatments with immune checkpoint inhibitors and platinum chemotherapy. The median progression-free survival (PFS) was reported at 11.1 months, with a 12-month PFS rate of 48%. Importantly, the safety profile appears manageable, with the majority of treatment-related adverse events being Grade 1 in severity. These results suggest that zoldonrasib could offer a more effective and less toxic alternative to conventional therapies for patients with KRAS G12D NSCLC.

The implications of these findings are substantial, as they may shift the paradigm in the treatment of KRAS G12D-driven cancers. The encouraging efficacy and safety data support the advancement of zoldonrasib into further clinical development, both as a monotherapy and in combination with other therapies. This could expedite the timeline for bringing targeted therapies to market for this challenging subset of lung cancer, potentially transforming treatment protocols and improving outcomes for patients with RAS-addicted malignancies.

Source: globenewswire.com